ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » South Dakota » Pulmonary Disease

Top Pulmonary Disease Prescribers in South Dakota

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
ROSS BACON M.D.

Pulmonary Disease

3,965

$689K

515
406 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

4%
patients receiving schedule three controlled substances

Avg: 0%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

41%
prescriptions for brand name drugs

Avg: 59%

$174
Average prescription price

Avg: $208

MICHAEL PIETILA M.D.

Pulmonary Disease

3,555

$238K

414
333 are 65+

4%
patients receiving schedule two controlled substances

Avg: 0%

5%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

31%
prescriptions for brand name drugs

Avg: 59%

$67
Average prescription price

Avg: $208

LORI HANSEN MD

Pulmonary Disease

3,506

$378K

320
267 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

48%
prescriptions for brand name drugs

Avg: 59%

$108
Average prescription price

Avg: $208

BRIAN HURLEY M.D.

Pulmonary Disease

2,573

$469K

350
285 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

63%
prescriptions for brand name drugs

Avg: 59%

$182
Average prescription price

Avg: $208

RIZAN HAJAL MD

Pulmonary Disease

1,913

$515K

250
192 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

48%
prescriptions for brand name drugs

Avg: 59%

$269
Average prescription price

Avg: $208

DAVID THOMAS M.D.

Pulmonary Disease

1,760

$445K

264
207 are 65+

6%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

44%
prescriptions for brand name drugs

Avg: 59%

$253
Average prescription price

Avg: $208

RICHARD HARDIE M.D.

Pulmonary Disease

1,649

$404K

263
210 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

65%
prescriptions for brand name drugs

Avg: 59%

$245
Average prescription price

Avg: $208

THOMAS REPAS DO

Pulmonary Disease

1,132

$179K

130
99 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

66%
prescriptions for brand name drugs

Avg: 59%

$158
Average prescription price

Avg: $208

FADY JAMOUS M.D.

Pulmonary Disease

1,108

$205K

171
134 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

72%
prescriptions for brand name drugs

Avg: 59%

$185
Average prescription price

Avg: $208

SUSAN ROHR DO

Pulmonary Disease

1,011

$397K

132
109 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

65%
prescriptions for brand name drugs

Avg: 59%

$392
Average prescription price

Avg: $208

ASHRAF ELSHAMI M.D.

Pulmonary Disease

992

$277K

172
141 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

69%
prescriptions for brand name drugs

Avg: 59%

$279
Average prescription price

Avg: $208

THOMAS LEMIRE MD

Pulmonary Disease

961

$565K

99
80 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

64%
prescriptions for brand name drugs

Avg: 59%

$588
Average prescription price

Avg: $208

JOHN YU M.D.

Pulmonary Disease

917

$383K

183
161 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

69%
prescriptions for brand name drugs

Avg: 59%

$418
Average prescription price

Avg: $208

DANIEL RAWSON MD

Pulmonary Disease

911

$252K

130
110 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

64%
prescriptions for brand name drugs

Avg: 59%

$277
Average prescription price

Avg: $208

JAMES MCCAFFERTY MD

Pulmonary Disease

833

$274K

117
105 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

65%
prescriptions for brand name drugs

Avg: 59%

$329
Average prescription price

Avg: $208

JEFFREY KOWITZ MD

Pulmonary Disease

722

$101K

138
111 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

53%
prescriptions for brand name drugs

Avg: 59%

$140
Average prescription price

Avg: $208

ELMO ROSARIO MD

Pulmonary Disease

645

$151K

78
64 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

72%
prescriptions for brand name drugs

Avg: 59%

$235
Average prescription price

Avg: $208

AMIT GUPTA MD

Pulmonary Disease

581

$66K

147
118 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

40%
prescriptions for brand name drugs

Avg: 59%

$114
Average prescription price

Avg: $208

DIVYA KAILA MD

Pulmonary Disease

459

$76.3K

118
69 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

87%
prescriptions for brand name drugs

Avg: 59%

$166
Average prescription price

Avg: $208

DEVIN BISSOON M.D.

Pulmonary Disease

356

$68.3K

51
39 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

62%
prescriptions for brand name drugs

Avg: 59%

$192
Average prescription price

Avg: $208

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank